ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
ImmunityBio(US:IBRX) Businesswire·2026-03-31 19:30公司融资动态 - ImmunityBio公司获得7500万美元非稀释性融资 该笔资金来自与Oberland Capital现有的特许权权益购买协议(RIPA) 使协议下的总承诺资本增加至3.75亿美元 [1] - 此次融资为修订后的协议 条款维持不变 特许权回报率略有提高 但特许权上限保持不变 [1] 公司业务定位 - ImmunityBio是一家垂直整合、处于商业化阶段的免疫治疗公司 [1]